Expansion opportunity Cerenome is expanding CNSide diagnostics coverage through in-network agreements (including HCSC with 150 million lives) and recent commercial sales leadership appointments, signaling strong traction potential with payers and health systems for CNS-related diagnostics and therapeutics.

Commercial ramp Recent senior appointment of VP of Commercial Sales and a financing facility to scale CNSide suggests accelerating commercial deployment and potential for partnerships with oncology practices, pathology groups, and hospital networks seeking cost-effective CSF tumor cell enumeration and CNS diagnostics.

Financing runway Up to 20 million in royalty-based financing extending cash runway into 2028 indicates resources to support scale-up, pilot programs, and expanded reimbursement demonstrations—opportunities to propose joint pilots with health systems to drive adoption.

Cost advantage Data highlights CNSide's potential to reduce monthly LM treatment costs by up to 47% and broader therapeutic–diagnostic integration, presenting a compelling value proposition for payers and health systems facing CNS cancer management costs.

Strategic positioning Integrated platform combining precision diagnostics, targeted therapeutics, and AI positions Cerenome to offer end-to-end CNS oncology solutions, creating cross-sell opportunities across diagnostics, therapeutics, and data-driven patient management with early engagement in oncology and neurology accounts.